
Joonbyrd Rewrites The Unspoken Rules Of Clinical Beauty
The Zoom call that changed Dr Alexis Granite's mind happened in her living room. Granite — a well-known dermatologist with nearly two decades of experience and the exceptionally rare distinction of holding dual US/UK medical licenses — was reviewing muted, clinical packaging mockups for her soon-to-launch skincare brand when her creative agency suddenly noticed something. Behind her on the video call was a room bursting with vibrant colors — quite the opposite to what they'd been developing.
'Wait a minute, like my living room is very, very colorful,' Granite recalls of that pivotal moment. 'And I was like, 'This is it!' I don't know why I'm hiding from what I love, which is color.'
That realization became key to the eventual birth of Joonbyrd, a body-focused luxury skincare brand that challenges assumptions about what serious, clinical skincare should look like. Entering Joonbyrd's website and social accounts, and you'll be greeted with all pastel hues of the rainbow. And the brand identity is fully reflected in its product packagings: vibrant, textured, fun and simply joy-inducing — quite a stark contrast to the sterile designs adopted by most other expert-led brands in the industry.
Joonbyrd's bodycare products are potent in active ingredients and designed to induce joy Courtesy of Joonbyrd
The decision to embrace color wasn't just about aesthetic — it was deeply personal. Granite's approach to skincare has always been rooted in the joyful memories of sitting in her grandmother's bathroom, playing with 'all of her lotions and potions, their deliciously sweet smells.' This 'joyful nostalgia' that she associates with beauty became the foundation for what she terms 'Affective Wellness' — a holistic approach connecting emotional well-being with skincare.
'I've seen time and time again, day in and day out in my practice, how much skin and appearance, frankly, is tied to emotion and I truly believe that when you look good, you feel good,' Granite explains. With a six-month waiting list for her London-based practice and a patient roster she's known for years, she's witnessed firsthand how stress impacts skin conditions like acne, eczema, and rosacea, and wants to provide an element in her brand to address this factor.
Speaking about perhaps her most counterintuitive decision on focusing solely on body care rather than facial skincare, Granite answers with a simple question: 'After all, why should the face have all the fun?'
Kaleidoscope, Joonbyrd's most recently launched body serum, smells like a cherry pie topped with pink peonies Courtesy of Joonbyrd
'I was seeing more and more patients come in with body skin concerns and clocking that over time, particularly in recent years,' she notes, while also recognizing that many treatments have now moved 'below the chin.'
The market gap was apparent. On one side were products focused purely on 'sensorial pleasure' — lovely bath salts and nice-smelling moisturizers without containing much of any active ingredients. On the other were clinical body products with 'that very sterile, quite medical feel.' Granite saw an opportunity: 'Why can't you have both? I want something that moisturizes amazingly, helps with crepey skin, improves keratosis pilaris bumps on the backs of the arms, but that also smells incredible.'
After much testing and formulation, her vision materialized through Joonbyrd's proprietary ALXmd04™ technology, built on four pillars: hardworking actives typically reserved for facial skincare, microbiome support, botanical extracts, and functional enhancers including adaptogens that 'sense what your body needs.' Even the fragrance for each product is designed to evoke specific moods — the caramel latte body wash aims for playfulness, while the cashmere musk firming serum targets optimism.
Fragrance and scent plays a big part in Joonbyrd's final products Courtesy of Joonbyrd
The transition from practicing dermatologist to beauty entrepreneur was not without its challenges. 'Becoming a brand founder has been one of, if not the most challenging part of my career — the only rival being medical school,' Granite says with a laugh. Yet her medical training provided crucial preparation: 'My degree definitely set me up for the challenges that I've faced as a founder.'
The biggest hurdle wasn't formulating products that delivered results — that came naturally after her consultancy/key opinion leader role over the past decade for brands like Kiehl's, SkinCeuticals, and CeraVe. Instead (and perhaps surprising to many,) it was convincing an industry accustomed to clinical aesthetics that serious skincare could also be joyful. 'I do think it is a bit more challenging to show the consumer that we're every bit as serious as a brand that doesn't look like us,' she acknowledges.
With Joonbyrd's exclusive Sephora launch under her belt and the brand's new launches receiving rave reviews from consumers (the brand's newest Kaleidoscope, a body serum supercharged with incredible ingredients and smells like a cherry pie topped with pink peonies, is to die for), it would seem that Granite is finally shifting the unspoken rules and proving that clinical excellence and joy aren't mutually exclusive.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Man with rare blood type makes 100th donation
A man with a rare blood type who made his 100th donation this year is encouraging others to give blood. Robert Boocock, from York, has been donating his rare B-negative blood for 40 years, after being inspired by his uncle, also a long-term donor. The 61-year-old is one of fewer than 20,000 B-negative blood donors in England, according to NHS Blood and Transplant. The NHS said it had lost almost 1,000 B-negative donors in the last year - or 5% of the B-negative donor base. When Mr Boocock was 21 and working for his uncle, he asked why he would regularly donate blood. "I hadn't realised that when I was quite young, my auntie had an operation that went slightly wrong, and she needed over 20 units of blood to make it through," he said. "That got me thinking, that's 20 people that can only donate once every few months. "I thought, I've got spare in my body, so why don't I volunteer?" 'Not going to stop' By donating over the years, Mr Boocock found out that his blood was suitable for newborns, who can only be transfused with blood lacking cytomegalovirus (CMV), a mild and common virus that most people catch as a child. "Occasionally when I donate, they say this one will be going to the neonatal ward," the donor said. "That's quite a nice thought that it's going straight to a little baby perhaps that doesn't know they need it." The NHS has appealed for younger donors to give blood, as up to 200,000 new donors are needed each year to replace those who stop donating. "I liken donating blood to a bank account, basically," Mr Boocock said. "Unless you put some in, how could you rely on there being some there when you may need it?" After 73 donations, his uncle had to stop for health reasons - which encouraged Mr Boocock to keep going. "Once I passed that, I thought, I'm not going to stop now. Let's see how many I can keep going with, until I no longer can," he said. "Hopefully that will be for many years to come." Listen to highlights from North Yorkshire on BBC Sounds, catch up with the latest episode of Look North. Related Internet links NHS Blood and Transplant


Bloomberg
an hour ago
- Bloomberg
Cranswick Muscles Up
Morning, I'm Louise Moon Social media health obsessions in recent years have spanned 'clean eating', superfoods and, lately, protein intake. That's helping Cranswick muscle up.
Yahoo
an hour ago
- Yahoo
Leerink Partners Decreases PT on Abbott Laboratories (ABT) to $136 From $143, Maintains a Hold Rating
Abbott Laboratories (NYSE:ABT) is one of the top low volatility healthcare stocks to buy now. Analyst Mike Kratky from Leerink Partners reiterated a Hold rating on Abbott Laboratories (NYSE:ABT) on July 21, decreasing the price target to $136.00 from $143.00. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The analyst justified the Hold rating with the company's performance, stating that Abbott Laboratories' (NYSE:ABT) recent Q2 earnings report presented a mixed picture. Management slashed their organic sales growth guidance, attributed primarily to several headwinds collectively affecting the Diagnostics segment outlook. These include changes in HIV funding, disruptions from value-based purchasing (VBP) in China, and weaker-than-expected COVID-19 sales. Kratky also stated that positive aspects for Abbott Laboratories (NYSE:ABT) exist amid these challenges, especially in the company's MedTech segment, which delivered solid growth. The non-MedTech segments are, however, continually facing complications, warranting a cautious outlook as these segments contribute significantly to the company's revenue. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells healthcare products. Its business segments include Diagnostic Products, Established Pharmaceutical Products, Medical Devices, and Nutritional Products. The company's Abbott Molecular is a leader in oncology molecular diagnostics with its Vysis FISH assays. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.